GSK is set to acquire Nuvalent, a Boston-based U.S. cancer drug specialist, as it looks to rebuild its oncology business. Multiple reports say the transaction is valued at about $10.6 billion, with one source also describing earlier talks for a price range of roughly $9 billion to $10 billion. Other outlets report the deal value in pounds, citing approximately £8 billion.
The acquisition is presented as one of GSK’s largest purchases in recent years, with reports characterizing it as the biggest deal in about eight years or more than a decade. GSK said it is strengthening its cancer pipeline, particularly in lung cancer. Coverage also notes that Nuvalent has two late-stage medicines and develops cancer drugs including several options for lung cancer.
The Financial Times-reported price range reflects that GSK had been in discussions prior to agreeing final terms. Overall reporting aligns on the parties involved, the focus on oncology and lung cancer, the approximate deal size, and the scale of the acquisition for GSK.
